Xeno-Free Integrated Platform for Robust Production of Cardiomyocyte Sheets from hiPSCs

Figure 3

Integration in the differentiation platform of a two-phase purification and enrichment step. (a) Addition of a purification step using 20 μM of PluriSin1 at day 6 and a purification/enrichment step at day 12 using glucose-free medium supplemented with lactate (Glu^-Lac⁺). (b) Simultaneous introduction of the two-step Plurisin1 and Glu^-Lac⁺ (P&L) increased differentiation efficiency in the system TeSR/Matrigel when compared with control. Error bars, SEM: for Control (6 μM), for P&L, for 1 : 2, for 1 : 2 P&L. value<0.01 (Welch’s -test). (c) Similar impact of Plurisin1 and Glu^-Lac⁺ was observed for the system TeSR/Synthemax when compared with control. Error bars, SEM: for Control (6 μM) and P&L, for 1 : 1, for 1 : 1 P&L. value<0.001 (Welch’s -test). (d) CM output at day 15 per seeded hiPSC for the system TeSR/Matrigel was not impacted significantly by P&L unless when replating was performed. Error bars, SEM: for Control (6 μM) and 1 : 2, for P&L and 1 : 2 P&L. value<0.05 (Welch’s -test). (e) Similarly, CM output for the system TeSR/Synthemax was not impacted significantly by P&L unless replating was performed. Error bars, SEM: for Control (6 μM) and P&L, for 1 : 1 and 1 : 1 P&L. value<0.05 (Welch’s -test).

(a)

(b)

(c)

(d)

(e)